CALLIDITAS THERAPEUTICS

Intended for US Healthcare professionals. This site is intended only for US residents. The products discussed in this site may have different product labeling in different countries... Tarpeyo targets mucosal B cells, which are responsible for the production of galactose-deficient IgA1 antibodies, causing IgAN7.

Also known as: Calliditas Therapeutics AB

Primary location: Stockholm Sweden